Open an account

MeiraGTx Holdings

MGTX · NASDAQ

$9.97+$0.52 (+5.50%)TodayMarket closed ·
Prev close $9.45

About MGTX

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. The company is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.

Employees
400
Headquarters
New York City, New York
Listed
Jun 8, 2018
Sector
Health Care
Industry
Biotechnology
Website
meiragtx.com

MGTX key statistics

Market cap
907.61M
Price-earnings ratio
13.31
Dividend yield
—
Average volume
1.10M
Volume
755.39K
Open price
$9.45
High today
$10.11
Low today
$9.41
52 Week high
$15.35
52 Week low
$6.62

MeiraGTx Holdings (MGTX) at a glance

As of Oct 20, 2026, MeiraGTx Holdings (MGTX) shares are priced at $9.97, giving the company a market cap of 907.61M and a price-to-earnings ratio of 13.31.

Today the stock has traded between $9.41 and $10.11. The current price is 6.0% above the day's low and 1.4% below its high.

Volume so far is 755.39K shares, below the average of 1.10M shares a day.

Over the past year MeiraGTx Holdings has ranged from $6.62 to $15.35, and now sits 38% of the way up that range.

MeiraGTx Holdings met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $1.71 per share against an estimate of -$0.4675.

The average analyst price target is $28.31, 183.9% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 10 analystsAvg $28.31
Low
$16.16
Now
$9.97
High
$52.50

MGTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 203.5% on average.

  1. Q3 FY24: reported -$0.55 per share against an estimate of -$0.5355
  2. Q4 FY24: reported -$0.50 per share against an estimate of -$0.5712
  3. Q1 FY25: reported -$0.51 per share against an estimate of -$0.4964
  4. Q2 FY25: reported -$0.48 per share against an estimate of -$0.4769
  5. Q3 FY25: reported -$0.62 per share against an estimate of -$0.4998
  6. Q4 FY25: reported $0.188 per share against an estimate of -$0.5814
  7. Q1 FY26: reported -$0.57 per share against an estimate of -$0.4095
  8. Q2 FY26: reported $1.71 per share against an estimate of -$0.4675

MGTX news

  • Press releasePRNewswire

    Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

  • Press releasePRNewswire

    Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

  • Vandana Singh

    Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • MeiraGTx Enters Into Asset Purchase Agreement With Johnson & Johnson To Buy All Interests In Bota-Vec For Treatment Of XLRP; MeiraGTx To Pay J&J $25M Upfront, Milestone Fees, High Double‑Digit Royalties On Bota‑Vec Sales

  • Press releaseGlobe Newswire

    MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

  • Press releaseGlobe Newswire

    MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

  • Press releaseGlobe Newswire

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

Similar companies

Companies in the same industry as MeiraGTx Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.